Dj Herbalife Price Target Raised To $17.00/Share From $11.00 By Citigroup

What Happened?

Shares of health and wellness products company Herbalife jumped 3.4% in the morning session after an analyst upgraded the company's stock to 'Buy' following strong third-quarter results. 

Argus raised its rating and set a price target of $15 for Herbalife, citing expected revenue growth from new products. This positive view was supported by the company's recent performance. In its third-quarter 2025 earnings report, Herbalife posted revenue of $1.3 billion, which surpassed the anticipated $1.26 billion. 

The company also achieved an earnings per share of $0.50, beating the forecast of $0.46. The broader sentiment from analysts appeared positive, with a consensus 'Buy' rating noted across the board.

After the initial pop the shares cooled down to $14.02, up 3.9% from previous close.

Is now the time to buy Herbalife? Access our full analysis report here.

What Is The Market Telling Us

Herbalife’s shares are extremely volatile and have had 30 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.

The previous big move we wrote about was 3 days ago when the stock dropped 2.8% on the news that investor concerns grew over the company's financial health, highlighted by shrinking sales and sluggish growth forecasts. 

Analysis pointed to shrinking unit sales over the previous two years and a projected sales growth of only 2.9% for the next twelve months, suggesting weak demand. Furthermore, the company's earnings per share had decreased more than its revenue, partly because it diluted shareholders. 

Adding to the negative sentiment were potential business risks, including regulatory compliance and uncertain consumer demand. An analyst from Mizuho also previously set a price target of $11.00, which implied an expectation for the stock to fall.

Herbalife is up 110% since the beginning of the year, and at $14.02 per share, has set a new 52-week high. Investors who bought $1,000 worth of Herbalife’s shares 5 years ago would now be looking at an investment worth $287.12.

What a fantastic six months it’s been for Herbalife. Shares of the company have skyrocketed 48.3%, hitting $11.76. This run-up might have investors contemplating their next move.

Is there a buying opportunity in Herbalife, or does it present a risk to your portfolio? Get the full stock story straight from our expert analysts, it’s free for active Edge members.

Why Is Herbalife Not Exciting?

We’re glad investors have benefited from the price increase, but we don't have much confidence in Herbalife. Here are three reasons we avoid HLF and a stock we'd rather own.

1. Demand Slipping as Sales Volumes Decline

Revenue growth can be broken down into changes in price and volume (the number of units sold). While both are important, volume is the lifeblood of a successful staples business as there’s a ceiling to what consumers will pay for everyday goods; they can always trade down to non-branded products if the branded versions are too expensive.

Herbalife’s average quarterly sales volumes have shrunk by 3.5% over the last two years. This decrease isn’t ideal because the quantity demanded for consumer staples products is typically stable.

2. Projected Revenue Growth Is Slim

Forecasted revenues by Wall Street analysts signal a company’s potential. Predictions may not always be accurate, but accelerating growth typically boosts valuation multiples and stock prices while slowing growth does the opposite.

Over the next 12 months, sell-side analysts expect Herbalife’s revenue to rise by 2.9%. While this projection suggests its newer products will spur better top-line performance, it is still below the sector average.

3. EPS Trending Down

We track the change in earnings per share (EPS) because it highlights whether a company’s growth is profitable.

Sadly for Herbalife, its EPS declined by 15.9% annually over the last three years, more than its revenue. This tells us the company struggled because its fixed cost base made it difficult to adjust to shrinking demand.

Final Judgment

Herbalife isn’t a terrible business, but it isn’t one of our picks. Following the recent rally, the stock trades at 4.6× forward P/E (or $11.76 per share). While this valuation is reasonable, we don’t really see a big opportunity at the moment. We're fairly confident there are better stocks to buy right now. Let us point you toward the most dominant software business in the world.

What Happened?

Shares of health and wellness products company Herbalife fell 2.8% in the morning session after investor concerns grew over the company's financial health, highlighted by shrinking sales and sluggish growth forecasts. 

Analysis pointed to shrinking unit sales over the previous two years and a projected sales growth of only 2.9% for the next twelve months, suggesting weak demand. Furthermore, the company's earnings per share had decreased more than its revenue, partly because it diluted shareholders. Adding to the negative sentiment were potential business risks, including regulatory compliance and uncertain consumer demand. An analyst from Mizuho also previously set a price target of $11.00, which implied an expectation for the stock to fall.

The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Herbalife? Access our full analysis report here.

What Is The Market Telling Us

Herbalife’s shares are very volatile and have had 28 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.

The previous big move we wrote about was 12 days ago when the stock gained 10.8% on the news that Argus Research upgraded its rating on the company's stock to 'Buy' from 'Hold' and set a new price target of $15. .

The research firm pointed to expected revenue growth from new products as the key reason for its positive view. Argus projected that Herbalife would achieve mid-single-digit revenue growth in 2025, which would end a three-year period of declines. The firm specifically noted two products, a skin-health product called HL/Skin and a weight-loss supplement named MultiBurn, as likely drivers for accelerated growth in 2026. The upgrade suggested a potential positive outlook for the company's future performance.

Herbalife is up 77.5% since the beginning of the year, but at $11.86 per share, it is still trading 11.1% below its 52-week high of $13.34 from November 2025. Investors who bought $1,000 worth of Herbalife’s shares 5 years ago would now be looking at an investment worth $240.03.